8 hasil untuk "Shuo FENG"
Menampilkan 1–8 · 2,09 detik · RSS
-
Artikel Jurnal Teks lengkap
Intelligent driving intelligence test for autonomous vehicles with naturalistic and adversarial environment
Driving intelligence tests are critical to the development and deployment of autonomous vehicles. The prevailing approach tests autonomous vehicles in life-like simulations of the naturalistic driving environment. However, due to the high dimensionality of the environment and the rareness of…
-
Artikel Jurnal Teks lengkap
Testing Scenario Library Generation for Connected and Automated Vehicles, Part I: Methodology
Testing and evaluation is a critical step in the development and deployment of connected and automated vehicles (CAVs), and yet there is no systematic framework to generate testing scenario library. This study aims to provide a general framework for the testing scenario library generation (TSLG)…
-
Artikel Jurnal Teks lengkap
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
BACKGROUND: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant. METHODS: Volunteers (aged ≥18 years)…
-
Artikel Jurnal Teks lengkap
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Abstract The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was…
-
Artikel Jurnal Teks lengkap
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
BACKGROUND: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks. The planned roll-out in the UK will involve…
-
Artikel Jurnal Teks lengkap
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis…